Characterizing the host response to rhBMP-2 in a rat spinal arthrodesis model

Spine

Volumn 38, Issue 12, 2013, Pages

  Hsu, Wellington K ^a   Polavarapu, Mahesh ^a   Riaz, Rehan ^a   Larson, Andrew C ^a   Diegmueller, Jared J ^b   Ghodasra, Jason H ^a   Hsu, Erin L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Medtronic Sofamor Danek   (United States)

Author keywords

BMP; BMP 2; Bone morphogenetic protein; Bone resorption; Complications; Cytokine; Magnetic resonance imaging; Mechanism; MRI; Osteolysis; RhBMP 2

Indexed keywords

COLLAGEN SPONGE; CXCL3 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTACOID; BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; CYTOKINE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE GRAFT; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG MEGADOSE; FEMALE; ILIAC CREST; MUSCLE RESECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALPATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; SPINE FUSION; ADVERSE EFFECTS; ANIMAL; ANIMAL MODEL; AUTOGRAFT; BLOOD; BONE TRANSPLANTATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; FISCHER 344 RAT; HUMAN; ILIAC BONE; LUMBAR VERTEBRA; METABOLISM; OSTEOLYSIS; PATHOLOGY; SEROMA; SURGERY; SURGICAL SPONGE; TIME; TRANSPLANTATION;

ANIMALS; AUTOGRAFTS; BONE MORPHOGENETIC PROTEIN 2; BONE TRANSPLANTATION; CYTOKINES; FEMALE; HUMANS; ILIUM; INFLAMMATION MEDIATORS; LUMBAR VERTEBRAE; MAGNETIC RESONANCE IMAGING; MODELS, ANIMAL; OSTEOLYSIS; RATS, INBRED F344; RECOMBINANT PROTEINS; SEROMA; SPINAL FUSION; SURGICAL SPONGES; TIME FACTORS;

EID: 84879076950     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31828cb977     Document Type: Article

References (38)

1. Buttermann GR. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J 2008; 8: 426-35.
2. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (Phila Pa 1976) 2003; 28: 1219-24; discussion 1225.
3. Boden SD, Zdeblick TA, Sandhu HS, et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (Phila Pa 1976) 2000; 25: 376-81.
4. Dimar JR 2nd, Glassman SD, Burkus JK, et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 2009; 91: 1377-86.
5. Dawson E, Bae HW, Burkus JK, et al. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial. J Bone Joint Surg Am 2009; 91: 1604-13.
6. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. Jama 2009; 302: 58-66.
7. Ong KL, Villarraga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 2010; 35: 1794-800.
8. Muchow RD, Hsu WK, Anderson PA. Histopathologic inflammatory response induced by recombinant bone morphogenetic protein- 2 causing radiculopathy after transforaminal lumbar interbody fusion. Spine J 2010; 10: e1-6.
9. Pradhan BB, Bae HW, Dawson EG, et al. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2006; 31: E277-84.
10. Vaidya R. Transforaminal interbody fusion and the "off label" use of recombinant human bone morphogenetic protein-2. Spine J 2009; 9: 667-9.
11. Vaidya R, Sethi A, Bartol S, et al. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech 2008; 21: 557-62.
12. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006; 19: 483-6.
13. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of offlabel PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008; 8: 1011-8.
14. Brower RS, Vickroy NM. A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5. Spine (Phila Pa 1976) 2008; 33: E653-5.
15. Toth JM, Boden SD, Burkus JK, et al. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976) 2009; 34: 539-50.
16. Marusic A, Grcevic D, Katavic V, et al. Role of B lymphocytes in new bone formation. Lab Invest 2000; 80: 1761-74.
17. Marusic A, Katavic V, Grcevic D, et al. Genetic variability of new bone induction in mice. Bone 1999; 25: 25-32.
18. Lee KB, Taghavi CE, Song KJ, et al. Inflammatory characteristics of rhBMP-2 in vitro and in an in vivo rodent model. Spine (Phila Pa 1976) 2011; 36: E149-54.
19. Deckers MM, van Bezooijen RL, van der Horst G, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblastderived vascular endothelial growth factor A. Endocrinology 2002; 143: 1545-53.
20. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004; 2: 141-9.
21. Raida M, Heymann AC, Gunther C, et al. Role of bone morphogenetic protein 2 in the crosstalk between endothelial progenitor cells and mesenchymal stem cells. Int J Mol Med 2006; 18: 735-9.
22. Rothhammer T, Bataille F, Spruss T, et al. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 2007; 26: 4158-70.
23. Otsuka E, Notoya M, Hagiwara H. Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. Calcif Tissue Int 2003; 73: 72-7.
24. Hsu WK, Wang JC, Liu NQ, et al. Stem cells from human fat as cellular delivery vehicles in an athymic rat posterolateral spine fusion model. J Bone Joint Surg Am 2008; 90: 1043-52.
25. Wang JC, Kanim LE, Yoo S, et al. Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Bone Joint Surg Am 2003; 85-A: 905-11.
26. Guo Y, Zhang Y, Klein R, et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res 2010; 70: 1555-63.
27. Tsai WL, Cheng JS, Lai KH, et al. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma-a long-term follow-up study. Aliment Pharmacol Ther 2008; 28: 304-11.
28. He T, Gatehouse PD, Kirk P, et al. Myocardial T*2 measurement in iron-overloaded thalassemia: an ex vivo study to investigate optimal methods of quantification. Magn Reson Med 2008; 60: 350-6.
29. Hsu WK, Polavarapu M, Riaz R, et al. Nanocomposite therapy as a more efficacious and less inflammatory alternative to bone morphogenetic protein-2 in a rodent arthrodesis model. J Orthop Res 2011; 29: 1812-9.
30. Urist MR. Bone: formation by autoinduction. Science 1965; 150: 893-9.
31. Akamaru T, Suh D, Boden SD, et al. Simple carrier matrix modifications can enhance delivery of recombinant human bone mor- phogenetic protein-2 for posterolateral spine fusion. Spine 2003; 28: 429-34.
32. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009; 11: 221.
33. Tsubaki M, Kato C, Manno M, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem 2007; 304: 53-60.
34. Goto KT, Kajiya H, Nemoto T, et al. Hyperocclusion stimulates osteoclastogenesis via CCL2 expression. J Dent Res 2011; 90: 793-8.
35. Mroz TE, Wang JC, Hashimoto R, et al. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 2010; 35: S86-104.
36. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein- 2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006; 31: 542-7.
37. Suh DY, Boden SD, Louis-Ugbo J, et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine (Phila Pa 1976) 2002; 27: 353-60.
38. Bae HW, Zhao L, Kanim LE, et al. Intervariability and intravariability of bone morphogenetic proteins in commercially available demineralized bone matrix products. Spine (Phila Pa 1976) 2006; 31: 1299-306; discussion 1307-8.